Lan Xu

PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

Jian Ding, Ling-hua Meng, Landian Hu, 2021, Journal for ImmunoTherapy of Cancer.

PET-Guided Evaluation and Optimization of Internalized Antibody–Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor

Xiaoyuan Chen, G. Niu, D. Kiesewetter, 2017, The Journal of Nuclear Medicine.

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

M. Rebelatto, J. Osbourn, Herren Wu, 2016, Cancer cell.

Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.

Yi Chen, Ling-hua Meng, Jian Ding, 2021, Cancer letters.

Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells

Ling-hua Meng, Landian Hu, Jiangqing Ding, 2021, Cell death & disease.

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

M. Rebelatto, J. Osbourn, Herren Wu, 2016, Cancer cell.